CENCORA: FORMERLY AMERISOURCEBERGEN
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.cencora.com
CENCORA THINKLIVE CELL AND GENE THERAPY VIRTUAL SUMMIT 2025
The Cencora ThinkLive Cell and Gene Therapy Virtual Summit 2025, held May 20 – 21, 2025, gathered industry leaders, healthcare experts, and innovators to explore the latest advancements in cell and gene therapy. With over 30 speakers and 11 informative sessions across six tracks, the summit provided a platform for discussing critical topics such as the evolving regulatory landscape, patient support programs, and strategic partnerships aimed at enhancing patient access to therapies. Esteemed speakers shared their insights on the challenges faced by health systems in administering these innovative treatments and the importance of aligning patient services with real patient needs.
CELL & GENE THERAPIES
Your therapy can make all the difference. Together, we'll unlock its potential.
CONTACT INFORMATION
Cencora
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
FEATURED INSIGHTS
-
![Gene therapy iStock-1300754583]( "ThinkLive Cell and Gene Therapy Summit 2025 Summary")
From patient support to intricate logistics, ThinkLive CGT Summit 2025 leaders tackled the essential commercial strategies needed to deliver these innovative therapies to patients globally.
-
![GettyImages-1443965506 doctor clinical trial data monitoring]( "Navigating Regulatory Complexity In CGT Development, Commercialization")
To successfully commercialize cell and gene therapies, understanding evolving US regulatory mandates is key. Consider these strategies to avoid delays and ensure compliance.
-
![GettyImages-953088038 patient network]( "Addressing Market Access Challenges As CGTs Expand To Larger Patient Populations")
Navigating market access for advanced therapies requires new strategies. Explore ways to boost payer understanding, innovate pricing, and adapt treatment settings as these therapies expand.
-
![GettyImages-1838438985 opthamology]( "The Future Promise Of Advanced Therapies In Ophthalmology")
Six years after the first approved gene therapy in ophthalmology, the field is experiencing a surge of activity. Delve into the exciting potential of advanced therapies for eye diseases.
-
![GettyImages-1414481878 clinical trial, patient, diversity]( "Navigating Patient Access Challenges When Bringing Your CGT Product To Market")
Bringing cell and gene therapies to market requires more than scientific breakthroughs; manufacturers must navigate complex patient access challenges to ensure these innovations reach those in need.
-
![GettyImages-1463492154 nurse]( "Optimizing The Channel Strategy To Expand Patient Access")
Patient access depends on a well-planned channel strategy. Explore key considerations for optimizing distribution, logistics, and patient support in the evolving cell and gene therapy landscape.
EXPLORE OUR THOUGHT LEADERSHIP
Explore the latest insights from the Cencora team.
VIDEOS AND WEBINARS
-
![Cencora - ATMP webinar Q&A]( "Q&A Interview: Navigating The Launch Of ATMPs In Europe")
Q&A Interview: Navigating The Launch Of ATMPs In EuropeDive into this overview of the evolving regulatory landscape and better understand the importance of proactive planning, collaboration, and expert guidance in navigating the ATMPs ecosystem in Europe.
-
![GettyImages-1196710772 doctors]( "Streamlining Patient Access To Cell And Gene Therapies")
Streamlining Patient Access To Cell And Gene TherapiesLearn about the obstacles patients encounter when seeking CGTs and explore how technology and patient services can empower manufacturers and clinical teams to help patients overcome barriers.
-
![Clinical Collaboration GettyImages-1288871608]( "Webinar: Reimbursement Methods For Sustainable CGT Business Models")
Webinar: Reimbursement Methods For Sustainable CGT Business ModelsLearn more about the key features of successful innovative pricing and reimbursement models as well as outcomes-based agreements and the ways to advance those strategies for cell and gene therapies.
-
![phlexglobal webinar 1]( "How Standardized Terminology Can Accelerate Global Regulatory Performance")
How Standardized Terminology Can Accelerate Global Regulatory PerformanceWatch this panel of regulatory experts taking part in an interactive roundtable examining the benefits of establishing standard terminology and its potential to help significantly improve regulatory quality, data accuracy, and efficiency.
-
![medical data regulatory GettyImages-970438352]( "Is EU CTR Driving Tighter Clinical & Regulatory Integration?")
Is EU CTR Driving Tighter Clinical & Regulatory Integration?The new Clinical Trials Regulation (EU) 536/2014 has raised critical questions about business process and data interactions between Clinical and Regulatory in biopharmaceutical companies. Did you know that as of 6 March 2022, there were more than 200 draft applications in CTIS?
BLOGS
-
![GettyImages-1480558197 Business Corporate Team Meeting]( "Enabling Market Access As CGTs Reach More Patients")
Enabling Market Access As CGTs Reach More PatientsBringing potentially curative cell and gene therapies to more patients requires a focused approach to market access. Discover essential insights into payer dynamics, pricing innovations, and treatment evolution.
-
![GettyImages-1495393006 opthalmology, eye care]( "A Bright Future For Eye Care: The Advanced Therapy Revolution Is Here")
A Bright Future For Eye Care: The Advanced Therapy Revolution Is HereGroundbreaking cell and gene therapies are revolutionizing eye care. Discover how advanced treatments target root causes, offering unprecedented hope for conditions previously deemed untreatable.
-
![Doctor talking to patient-GettyImages-1330555438]( "Navigating Patient Access Challenges In Commercializing Your CGT Product")
Navigating Patient Access Challenges In Commercializing Your CGT ProductLearn how to effectively break down barriers to patient access in cell and gene therapy by enhancing provider education, streamlining coordination, and expanding patient support.
-
![GettyImages-1938542776 doctor patient]( "Expanding Patient Access To Cell And Gene Therapies: Optimizing Channel Strategy")
Expanding Patient Access To Cell And Gene Therapies: Optimizing Channel StrategyRare disease innovation demands robust channel strategies for patient access. Learn how a patient-centric approach, logistical solutions, and strong partnerships are key to successful patient access.
-
![GettyImages-547131922 research, regulatory, lab]( "Navigating The CGT Landscape: Key Takeaways From The FDA's New FAQ")
Navigating The CGT Landscape: Key Takeaways From The FDA's New FAQThe FDA's new FAQ on cell and gene therapy offers a roadmap for developers. Review key insights from the document, including the importance of early engagement with the FDA, CMC considerations, and more.
